






































































Inhibition of placental CYP19A1 activity remains
as a valid hypothesis for 46,XX virilization in
P450 oxidoreductase deficiency
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Cytochrome P450 oxidoreductase deficiency (PORD),1 caused by mutations in P450 oxidoreductase (POR), is2
a disorder of steroid metabolism often characterized by dis-3
ordered sexual development (1–3). POR is required for enzy-4
matic activities of multiple cytochrome P450 enzymes (4). In5
PNAS, Reich et al. (5) propose “alternative pathway andro-6
gen biosynthesis” as the cause of 46,XX virilization in PORD.7
We are pleased to see the expansion of the role of alterna-8
tive pathway in sexual development previously demonstrated9
by us in 46,XY individuals (6), but have some concerns re-10
garding the assumption that virilization of 46,XX individuals11
in PORD is mainly via alternative pathway. The choice of12
steroid analysis by Reisch et al. (5) from only 46,XY individ-13
uals to propose a hypothesis for 46,XX virilization is baffling.14
Another recent study found low to undetectable levels of 17-15
hydroxy-dihydroprogesterone, 17-hydroxy-allopregnanolone,16
and androsterone, the steroids in alternative pathway produced17
via CYP17A1, in the 46,XX fetal adrenals and attributed it18
to a lack of SRD5A1 expression in fetal adrenal (7). We have19
previously reported that mutations in the key enzymes of the20
alternative pathway cause 46,XY undervirilization (6). By21
contrast, mutations in aromatase (CYP19A1) cause genital22
virilization in 46,XX individuals (8), which prompted us to23
reexamine the results of Reisch et al. (5).24
Mutations in POR reduce the enzymatic activities of25
CYP17A1 (Fig. 1A) (1–4). Reisch et al. (5) reported that an26
androgen produced via alternative pathway, using CYP17A127
and POR, is not severely impacted by A287P mutation in28
POR, but enzyme kinetic analysis was not performed. The29
A287P mutation in POR inhibits CYP17A1 activity but also30
reduces enzyme turnover/maximum velocity by 40 percent in31
CYP19A1 assays using androstenedione (Fig. 1B) . Therefore,32
the assumption of Reisch et al. (5) that aromatase activity is33
unimpacted by A287P mutation in POR is incorrect . Hep-34
atic cytochromes P450, including CYP3A4, can metabolize35
steroids, and A287P mutation in POR inhibited CYP3A436
activity (Fig. 1C). Although the methods are not directly37
comparable, in our assays, activities of multiple enzymes were38
adversely affected by A287P mutation in POR (Fig. 1D).39
We have described the role of CYP19A1 in 46,XX virilization40
with PORD (9). Interestingly, maternal virilization during41
pregnancy is a specific feature almost exclusively observed42
in cases with CYP19A1 deficiency (10) or maternal tumor.43
In fact, maternal virilization during pregnancy is common in44
PORD but not in 21-hydroxylase deficiency, although both45
conditions are associated with alternative pathway androgen46
biosynthesis (2, 4–6, 9). These data strongly suggest that pla-47
cental aromatase deficiency is the major cause of virilization of48
46,XX PORD patients. Therefore, the study by Reisch et al.49
(5) confirms a role of “alternative pathway androgen produc- 50
tion” in 46,XY PORD, but does not negate the role of reduced 51
CYP19A1 activity due to POR mutations. Consequently, both 52
the alternative pathway androgen production and inhibition of 53
aromatase activity in PORD may cause genital virilization of 54
46,XX patients. 46,XX virilization in PORD requires further 55
exploration, and polymorphisms of POR, cytochromes P450 56
and related genes may play a role in phenotype variations (4). 57
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Fig. 1. Impact of mutations in POR on enzymatic
activities of cytochrome P450 enzymes. A. Impact of
mutations in POR on the activities of steroid metabo-
lizing cytochrome P450 enzymes. POR is necessary
for the metabolic activities of cytochrome P450 pro-
teins located in the endoplasmic reticulum (4). These
include the steroid metabolizing cytochromes P450
CYP17A1, CYP21A2, CYP19A1, CYP51A1, and
CYP26B1 as well as drug-metabolizing cytochromes
P450 CYP3A4, CYP3A5, CYP2D6, CYP2C9 and
CYP2C19. A reduction in POR activity may lead to
loss of both the steroid as well as drug-metabolizing
cytochromes P450 enzyme activities. Further con-
siderations might be required for drug-metabolizing
enzymes like CYP3A4 that also cause hepatic
metabolism of estrogens and androgens. B. Enzy-
matic activity of CYP19A1 supported by POR-wild
type (WT) and POR-A287P. Recombinant CYP19A1
and POR proteins were mixed with lipids, and their
activity to convert [3H] androstenedione to estrone
was tested by the tritiated water release assay (9).
Data were analyzed using the Michaelis-Menten
kinetics with GraphPad Prism. C. The activity of
cytochrome P450 CYP3A4 supported by POR-WT
and POR-A287P. Assay of CYP3A4 activity was per-
formed to compare POR-WT and POR-A287P by
using BOMCC as a substrate (9). D. The activity
of cytochrome P450 CYP3A4, CYP3A5, CYP2C9,
and CYP2C19 supported by POR-WT and POR-
A287P. Assay of CYP3A4, CYP3A5 and CYP2C9
activity was performed to compare POR-WT and
POR-A287P by using BOMCC as a substrate and
assay of CYP2C19 activity was performed to com-
pare POR-WT and POR-A287P by using EOMCC
as a substrate (9). Activity with the WT POR was
fixed as a hundred percent in all cases, and results
are given as a percentage of WT activity. Data are
shown as mean ± SEM from triplicate assays.
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